Company Active LTD

Company profile

Daresbury Proteins LTD.

Home | Daresbury Proteins Ltd. Mammalian recombinant production.

Daresbury Proteins Ltd is specialising in mammalian recombinant protein production and cell line development. We are producing authentic mammalian recombinants such as difficult-to-express proteins as reagents or candidate targets. Our proprietary expression technology outperforms existing approaches.

CRN
10835544
Founded
2017
Age
9

Overview

Legal name
DARESBURY PROTEINS LTD.
Region
North West England
Registered address
ITAC-BIO 19 SCI-TECH DARESBURY
KECKWICK LANE
WARRINGTON
ENGLAND
WA4 4AD
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

5 events
04 May
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Mar
2027

Accounts due

Accounts Due

Next accounts due date

20 Apr
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Jun
2025

Accounts filed

Accounts

Last accounts made up date

26 Jun
2017

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2020
Funded years
2020, 2022, 2024, 2025
Age at first award
3 years

Projects

2025 Collaborative R&D Lead participant

Next Generation ADC platform

1 Apr 2025 to 31 Mar 2027

Awarded
£325,476
Total cost £464,965

The proposed project aims to develop a novel expression platform for high-level production of monoclonal antibodies (mAbs) with optimized affinity peptide tags for development of advanced antibody drug conjugates (ADCs). The project brings together the expertise from Daresbury Proteins Ltd ("Daresbury"), a UK-based company specializing in novel expression...

2024 Collaborative R&D

Active Protein Factory for cost-effective Cellular Agriculture media

1 Oct 2024 to 31 Mar 2025

Awarded
£8,500
Total cost £8,500

Lab-grown meat represents a new frontier in Agriculture by which we might sustainably address the needs of a growing global population in an increasingly challenging environment for traditional farming. Yet considerable Manufacturing barriers remain in order for lab-grown meat to hit the price needed to make a meaningful impact upon Food Security and Sust...

2022 Collaborative R&D Lead participant

PRODARES

1 May 2022 to 30 Apr 2024

Awarded
£260,177
Total cost £433,628
2020 Collaborative R&D Lead participant

Scalable, sustainable and cost-effective antigen manufacturing platform for a rapid mobilisation during the current Covid-19 pandemic and possible future outbreaks

1 Oct 2020 to 30 Jun 2021

Awarded
£174,285
Total cost £217,856

The 21st century ushered the advent of coronaviral pandemics such as SARS in 2002-2004, MERS in 2012-2018 and presently Covid-19\. These infections killed hundreds of thousands of people yet we do not know how to treat or prevent them. Our inability to identify people affected by Covid-19, has led to the spread of the infection on a global scale, causing ...

Product types

Collaborative R&D